Affiliation:
1. Prof. Gisela Enders & Kollegen MVZ GbR, Stuttgart, Germany
Abstract
ABSTRACT
Quantitating the level of hepatitis C virus (HCV) RNA is the standard of care for monitoring HCV-infected patients during treatment. The performances of commercially available assays differ for precision, limit of detection, and limit of quantitation (LOQ). Here, we compare the performance of the Hologic Aptima HCV Quant Dx assay (Aptima) to that of the Roche Cobas TaqMan HCV test, version 2.0, using the High Pure system (HPS/CTM), considered a reference assay since it has been used in trials defining clinical decision points in patient care. The assays' performance characteristics were assessed using HCV RNA reference panels and plasma/serum from chronically HCV-infected patients. The agreement between the assays for the 3 reference panels was good, with a difference in quantitation values of <0.5 log. High concordance was demonstrated between the assays for 245 clinical samples (kappa = 0.80; 95% confidence interval [CI], 0.720 to 0.881); however, Aptima detected and/or quantitated 20 samples that HPS/CTM did not detect, while Aptima did not detect 1 sample that was quantitated by HPS/CTM. For the 165 samples quantitated by both assays, the values were highly correlated (
R
= 0.98;
P
< 0.0001). The linearity of quantitation from concentrations of 1.4 to 6 log was excellent for both assays for all HCV genotypes (GT) tested (GT 1a, 1b, 2b, and 3a) (
R
2
> 0.99). The assays had similar levels of total and intra-assay variability across all genotypes at concentrations from 1,000 to 25 IU/ml. Aptima had a greater analytical sensitivity, quantitating more than 50% of replicates at 25-IU/ml target. Aptima showed performance characteristics comparable to those of HPS/CTM and increased sensitivity, making it suitable for use as a clinical diagnostic tool on the fully automated Panther platform.
Publisher
American Society for Microbiology
Reference29 articles.
1. World Health Organization (WHO). July 2015 Hepatitis C. Fact sheet no. 164. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 19 November 2015.
2. World Health Organization (WHO). 2015. Hepatitis C in the WHO European Region. Fact sheet---July 2015. http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics/fact-sheet-hepatitis-c-in-the-who-european-region. Accessed 19 November 2015.
3. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). 2015. Monitoring patients who are starting hepatitis C treatment are on treatment or have completed therapy. In HCV guidance: recommendations for testing managing and treating hepatitis C. http://www.hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have. Accessed 11 November 2015.
4. EASL Recommendations on Treatment of Hepatitis C 2015
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献